Thomas Kindler

Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation

Richard F. Schlenk, Sabine Käyser, Lars Bullinger et al. · Blood · 2014 · 400 citations · Full text

Life Sciences, Genetics, Molecular Genetics +3

Monitoring of Minimal Residual Disease in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group

Jan Krönke, Richard F. Schlenk, Kai‐Ole Jensen et al. · Journal of Clinical Oncology · 2011 · 394 citations · Full text

Medicine, Hematology, Oncology +15

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

Richard F. Schlenk, Daniela Weber, Walter Fiedler et al. · Blood · 2018 · 288 citations · Full text

Medicine, Oncology, Pharmacology +12

Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

Peter Horak, Christoph Heining, Simon Kreutzfeldt et al. · Cancer Discovery · 2021 · 285 citations

Medicine, Molecular Genetics, Oncology +17

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

Florian H. Heidel, Fian K. Solem, Frank Breitenbuecher et al. · Blood · 2005 · 268 citations

Medicine, Oncology, Pharmacology +17